-
(
BaglivoS
LudoviniV
MorettiR
, et al. RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. Oncol Ther
2020; 8: 333–339.32700042)
BaglivoS
LudoviniV
MorettiR
, et al. RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. Oncol Ther
2020; 8: 333–339.32700042
BaglivoS
LudoviniV
MorettiR
, et al. RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. Oncol Ther
2020; 8: 333–339.32700042,
BaglivoS
LudoviniV
MorettiR
, et al. RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. Oncol Ther
2020; 8: 333–339.32700042
-
(
CuiW
CotterC
SreterKB
, et al. Case of fatal immune-related skin toxicity from sequential use of osimertinib after pembrolizumab: lessons for drug sequencing in never-smoking non–small-cell lung cancer. JCO Oncol Pract
2020; 16: 842–844.32915710)
CuiW
CotterC
SreterKB
, et al. Case of fatal immune-related skin toxicity from sequential use of osimertinib after pembrolizumab: lessons for drug sequencing in never-smoking non–small-cell lung cancer. JCO Oncol Pract
2020; 16: 842–844.32915710
CuiW
CotterC
SreterKB
, et al. Case of fatal immune-related skin toxicity from sequential use of osimertinib after pembrolizumab: lessons for drug sequencing in never-smoking non–small-cell lung cancer. JCO Oncol Pract
2020; 16: 842–844.32915710,
CuiW
CotterC
SreterKB
, et al. Case of fatal immune-related skin toxicity from sequential use of osimertinib after pembrolizumab: lessons for drug sequencing in never-smoking non–small-cell lung cancer. JCO Oncol Pract
2020; 16: 842–844.32915710
-
A.
Li,
M.
McCusker,
A.
Russo,
K.
Scilla,
A.
Gittens,
Katherine
Arensmeyer,
R.
Mehra,
V.
Adamo,
C.
Rolfo
(2019)
RET fusions in solid tumors.
Cancer treatment reviews, 81
-
J.
Mazières,
A.
Drilon,
A.
Lusque,
L.
Mhanna,
A.
Cortot,
L.
Mezquita,
A.
Thai,
C.
Mascaux,
S.
Couraud,
R.
Veillon,
M.
Heuvel,
J.
Neal,
N.
Peled,
M.
Früh,
T.
Ng,
V.
Gounant,
S.
Popat,
J.
Diebold,
J.
Sabari,
V.
Zhu,
S.
Rothschild,
P.
Bironzo,
A.
Martínez-Martí,
A.
Curioni-Fontecedro,
R.
Rosell,
Mickaël
Lattuca-Truc,
M.
Wiesweg,
B.
Besse,
B.
Solomon,
F.
Barlesi,
R.
Schouten,
H.
Wakelee,
D.
Camidge,
G.
Zalcman,
S.
Novello,
S.
Ou,
J.
Milia,
O.
Gautschi
(2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Annals of Oncology, 30
-
(
LiAY
McCuskerMG
RussoA
, et al. RET fusions in solid tumors. Cancer Treat Rev
2019; 81: 101911.31715421)
LiAY
McCuskerMG
RussoA
, et al. RET fusions in solid tumors. Cancer Treat Rev
2019; 81: 101911.31715421
LiAY
McCuskerMG
RussoA
, et al. RET fusions in solid tumors. Cancer Treat Rev
2019; 81: 101911.31715421,
LiAY
McCuskerMG
RussoA
, et al. RET fusions in solid tumors. Cancer Treat Rev
2019; 81: 101911.31715421
-
W.
Cui,
Chantal
Cotter,
K.
Sreter,
K.
Heelan,
D.
Creamer,
T.
Basu,
J.
Handy,
S.
Walsh,
S.
Popat
(2020)
Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung Cancer.
JCO oncology practice
-
(
BronteG
UliviP
VerlicchiA
, et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer (Auckl)
2019; 10: 27–36.30962732)
BronteG
UliviP
VerlicchiA
, et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer (Auckl)
2019; 10: 27–36.30962732
BronteG
UliviP
VerlicchiA
, et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer (Auckl)
2019; 10: 27–36.30962732,
BronteG
UliviP
VerlicchiA
, et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer (Auckl)
2019; 10: 27–36.30962732
-
A.
Calles,
J.
Riess,
J.
Brahmer
(2020)
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40
-
(
HessLM
HanY
ZhuYE
, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer
2021; 21: 28.33402119)
HessLM
HanY
ZhuYE
, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer
2021; 21: 28.33402119
HessLM
HanY
ZhuYE
, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer
2021; 21: 28.33402119,
HessLM
HanY
ZhuYE
, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer
2021; 21: 28.33402119
-
E.
Eisenhauer,
P.
Therasse,
J.
Bogaerts,
L.
Schwartz,
D.
Sargent,
R.
Ford,
J.
Dancey,
S.
Arbuck,
S.
Gwyther,
M.
Mooney,
Lawrence
Rubinstein,
L.
Shankar,
L.
Dodd,
Robert
Kaplan,
D.
Lacombe,
J.
Verweij
(2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
European journal of cancer, 45 2
-
(
McCoachC
TanD
BesseB
, et al. Hypersensitivity reactions to selpercatinib in patients with RET-fusion-positive non-small cell lung cancer (NSCLC). Presented at ESMO Virtual Congress, 19–21 September 2020. Abstract P1054.)
McCoachC
TanD
BesseB
, et al. Hypersensitivity reactions to selpercatinib in patients with RET-fusion-positive non-small cell lung cancer (NSCLC). Presented at ESMO Virtual Congress, 19–21 September 2020. Abstract P1054.
McCoachC
TanD
BesseB
, et al. Hypersensitivity reactions to selpercatinib in patients with RET-fusion-positive non-small cell lung cancer (NSCLC). Presented at ESMO Virtual Congress, 19–21 September 2020. Abstract P1054.,
McCoachC
TanD
BesseB
, et al. Hypersensitivity reactions to selpercatinib in patients with RET-fusion-positive non-small cell lung cancer (NSCLC). Presented at ESMO Virtual Congress, 19–21 September 2020. Abstract P1054.
-
(
CaveA
KurzX
ArlettP
. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther
2019; 106: 36–39.30970161)
CaveA
KurzX
ArlettP
. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther
2019; 106: 36–39.30970161
CaveA
KurzX
ArlettP
. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther
2019; 106: 36–39.30970161,
CaveA
KurzX
ArlettP
. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther
2019; 106: 36–39.30970161
-
(
WangH
WangZ
ZhangG
, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med
2020; 9: 487–495.31769228)
WangH
WangZ
ZhangG
, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med
2020; 9: 487–495.31769228
WangH
WangZ
ZhangG
, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med
2020; 9: 487–495.31769228,
WangH
WangZ
ZhangG
, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med
2020; 9: 487–495.31769228
-
(
MoseleF
RemonJ
MateoJ
, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol
2020; 31: 1491–1505.32853681)
MoseleF
RemonJ
MateoJ
, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol
2020; 31: 1491–1505.32853681
MoseleF
RemonJ
MateoJ
, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol
2020; 31: 1491–1505.32853681,
MoseleF
RemonJ
MateoJ
, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol
2020; 31: 1491–1505.32853681
-
A.
Drilon,
I.
Bergagnini,
L.
Delasos,
J.
Sabari,
K.
Woo,
A.
Plodkowski,
L.
Wang,
M.
Hellmann,
P.
Joubert,
C.
Sima,
R.
Smith,
R.
Somwar,
N.
Rekhtman,
M.
Ladanyi,
Gregory
Riely,
M.
Kris
(2016)
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 7
-
V.
Subbiah,
G.
Cote
(2020)
Advances in Targeting RET-Dependent Cancers.
Cancer discovery
-
F.
Mosele,
J.
Remon,
J.
Mateo,
C.
Westphalen,
F.
Barlesi,
M.
Lolkema,
N.
Normanno,
A.
Scarpa,
Mark
Robson,
F.
Meric-Bernstam,
N.
Wagle,
A.
Stenzinger,
J.
Bonastre,
A.
Bayle,
S.
Michiels,
I.
Bièche,
E.
Rouleau,
S.
Jezdic,
J.
Douillard,
J.
Reis-Filho,
R.
Dienstmann,
F.
André
(2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.
Annals of oncology : official journal of the European Society for Medical Oncology
-
Nicolas
Stransky,
E.
Cerami,
S.
Schalm,
Joseph
Kim,
C.
Lengauer
(2014)
The landscape of kinase fusions in cancer
Nature Communications, 5
-
G.
Bronte,
P.
Ulivi,
A.
Verlicchi,
P.
Cravero,
A.
Delmonte,
L.
Crinò
(2019)
Targeting RET-rearranged non-small-cell lung cancer: future prospects
Lung Cancer: Targets and Therapy, 10
-
(
WangR
HuH
PanY
, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol
2012; 30: 4352–4359.23150706)
WangR
HuH
PanY
, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol
2012; 30: 4352–4359.23150706
WangR
HuH
PanY
, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol
2012; 30: 4352–4359.23150706,
WangR
HuH
PanY
, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol
2012; 30: 4352–4359.23150706
-
V.
Subbiah,
Dong
Yang,
V.
Velcheti,
A.
Drilon,
F.
Meric-Bernstam
(2020)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
A.
Drilon,
Z.
Hu,
G.
Lai,
D.
Tan
(2018)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Nature Reviews Clinical Oncology, 15
-
O.
Gautschi,
J.
Milia,
T.
Filleron,
J.
Wolf,
D.
Carbone,
D.
Owen,
R.
Camidge,
V.
Narayanan,
R.
Doebele,
B.
Besse,
J.
Remon-Masip,
P.
Janne,
M.
Awad,
N.
Peled,
Chul-Cho
Byoung,
D.
Karp,
M.
Heuvel,
H.
Wakelee,
J.
Neal,
T.
Mok,
J.
Yang,
S.
Ou,
G.
Pall,
P.
Froesch,
G.
Zalcman,
D.
Gandara,
J.
Riess,
V.
Velcheti,
K.
Zeidler,
J.
Diebold,
M.
Früh,
S.
Michels,
I.
Monnet,
S.
Popat,
R.
Rosell,
N.
Karachaliou,
S.
Rothschild,
J.
Shih,
A.
Warth,
T.
Muley,
F.
Cabillic,
J.
Mazières,
A.
Drilon
(2017)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 13
-
W.
Cai,
C.
Su,
Xue-Fei
Li,
L.
Fan,
Li-mou
Zheng,
K.
Fei,
Caicun
Zhou
(2013)
KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer
Cancer, 119
-
(
SubbiahV
YangD
VelchetiV
, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol
2020; 38: 1209–1221.32083997)
SubbiahV
YangD
VelchetiV
, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol
2020; 38: 1209–1221.32083997
SubbiahV
YangD
VelchetiV
, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol
2020; 38: 1209–1221.32083997,
SubbiahV
YangD
VelchetiV
, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol
2020; 38: 1209–1221.32083997
-
S.
Baglivo,
V.
Ludovini,
R.
Moretti,
G.
Bellezza,
A.
Sidoni,
F.
Roila,
G.
Metro
(2020)
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
Oncology and Therapy, 8
-
L.
Hess,
Yimei
Han,
Y.
Zhu,
N.
Bhandari,
A.
Sireci
(2021)
Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
BMC Cancer, 21
-
B.
Osta,
S.
Ramalingam
(2020)
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
JTO Clinical and Research Reports, 1
-
(
StranskyN
CeramiE
SchalmS
, et al. The landscape of kinase fusions in cancer. Nat Commun
2014; 5: 4846.25204415)
StranskyN
CeramiE
SchalmS
, et al. The landscape of kinase fusions in cancer. Nat Commun
2014; 5: 4846.25204415
StranskyN
CeramiE
SchalmS
, et al. The landscape of kinase fusions in cancer. Nat Commun
2014; 5: 4846.25204415,
StranskyN
CeramiE
SchalmS
, et al. The landscape of kinase fusions in cancer. Nat Commun
2014; 5: 4846.25204415
-
(
DrilonA
BergagniniI
DelasosL
, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol
2016; 27: 1286–1291.27056998)
DrilonA
BergagniniI
DelasosL
, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol
2016; 27: 1286–1291.27056998
DrilonA
BergagniniI
DelasosL
, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol
2016; 27: 1286–1291.27056998,
DrilonA
BergagniniI
DelasosL
, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol
2016; 27: 1286–1291.27056998
-
(
TsutaK
KohnoT
YoshidaA
, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer
2014; 110: 1571–1578.24504365)
TsutaK
KohnoT
YoshidaA
, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer
2014; 110: 1571–1578.24504365
TsutaK
KohnoT
YoshidaA
, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer
2014; 110: 1571–1578.24504365,
TsutaK
KohnoT
YoshidaA
, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer
2014; 110: 1571–1578.24504365
-
V.
Subbiah,
V.
Velcheti,
Brian
Tuch,
K.
Ebata,
N.
Busaidy,
M.
Cabanillas,
L.
Wirth,
S.
Stock,
Steve
Smith,
V.
Lauriault,
S.
Corsi-Travali,
Dahlia
Henry,
M.
Burkard,
R.
Hamor,
K.
Bouhana,
S.
Winski,
R.
Wallace,
D.
Hartley,
S.
Rhodes,
M.
Reddy,
B.
Brandhuber,
S.
Andrews,
S.
Rothenberg,
A.
Drilon
(2018)
Selective RET kinase inhibition for patients with RET-altered cancers
Annals of Oncology, 29
-
(
EisenhauerEA
TherasseP
BogaertsJ
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer
2009; 45: 228–247.19097774)
EisenhauerEA
TherasseP
BogaertsJ
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer
2009; 45: 228–247.19097774
EisenhauerEA
TherasseP
BogaertsJ
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer
2009; 45: 228–247.19097774,
EisenhauerEA
TherasseP
BogaertsJ
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer
2009; 45: 228–247.19097774
-
(
GemmaA
KusumotoM
SakaiF
, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol
2020; 15: 1893–1906.32927121)
GemmaA
KusumotoM
SakaiF
, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol
2020; 15: 1893–1906.32927121
GemmaA
KusumotoM
SakaiF
, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol
2020; 15: 1893–1906.32927121,
GemmaA
KusumotoM
SakaiF
, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol
2020; 15: 1893–1906.32927121
-
(
BelliC
Penault-LlorcaF
LadanyiM
, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol
2021; 32: 337–350.33455880)
BelliC
Penault-LlorcaF
LadanyiM
, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol
2021; 32: 337–350.33455880
BelliC
Penault-LlorcaF
LadanyiM
, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol
2021; 32: 337–350.33455880,
BelliC
Penault-LlorcaF
LadanyiM
, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol
2021; 32: 337–350.33455880
-
A.
Drilon,
G.
Oxnard,
D.
Tan,
H.
Loong,
M.
Johnson,
J.
Gainor,
C.
McCoach,
O.
Gautschi,
B.
Besse,
B.
Cho,
N.
Peled,
J.
Weiss,
Yu-Jung
Kim,
Y.
Ohe,
M.
Nishio,
Keunchil
Park,
J.
Patel,
T.
Seto,
T.
Sakamoto,
Ezra
Rosen,
M.
Shah,
F.
Barlesi,
P.
Cassier,
L.
Bazhenova,
F.
Braud,
E.
Garralda,
V.
Velcheti,
M.
Satouchi,
K.
Ohashi,
N.
Pennell,
K.
Reckamp,
G.
Dy,
J.
Wolf,
B.
Solomon,
G.
Falchook,
K.
Ebata,
M.
Nguyen,
B.
Nair,
E.
Zhu,
Luxi
Yang,
Xin
Huang,
E.
Olek,
S.
Rothenberg,
K.
Goto,
V.
Subbiah
(2020)
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine, 383 9
-
Rui
Wang,
Haichuan
Hu,
Yunjian
Pan,
Yuan
Li,
T.
Ye,
Chenguang
Li,
Xiao-yang
Luo,
Lei
Wang,
Hang
Li,
Yang
Zhang,
Fei
Li,
Yong-ming
Lu,
Q.
Lu,
Jie
Xu,
D.
Garfield,
L.
Shen,
H.
Ji,
W.
Pao,
Yihua
Sun,
Haiquan
Chen
(2012)
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 35
-
(
CallesA
RiessJW
BrahmerJR
. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book
2020; 40: 372–384.32421452)
CallesA
RiessJW
BrahmerJR
. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book
2020; 40: 372–384.32421452
CallesA
RiessJW
BrahmerJR
. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book
2020; 40: 372–384.32421452,
CallesA
RiessJW
BrahmerJR
. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book
2020; 40: 372–384.32421452
-
A.
Cave,
X.
Kurz,
P.
Arlett
(2019)
Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
Clinical Pharmacology and Therapeutics, 106
-
(
GautschiO
MiliaJ
FilleronT
, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the Global, Multicenter RET Registry. J Clin Oncol
2017; 35: 1403–1410.28447912)
GautschiO
MiliaJ
FilleronT
, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the Global, Multicenter RET Registry. J Clin Oncol
2017; 35: 1403–1410.28447912
GautschiO
MiliaJ
FilleronT
, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the Global, Multicenter RET Registry. J Clin Oncol
2017; 35: 1403–1410.28447912,
GautschiO
MiliaJ
FilleronT
, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the Global, Multicenter RET Registry. J Clin Oncol
2017; 35: 1403–1410.28447912
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
A.
Drilon,
Jessica
Lin,
T.
Filleron,
A.
Ni,
J.
Milia,
I.
Bergagnini,
V.
Hatzoglou,
V.
Velcheti,
M.
Offin,
Bob
Li,
D.
Carbone,
B.
Besse,
T.
Mok,
M.
Awad,
J.
Wolf,
D.
Owen,
D.
Camidge,
Gregory
Riely,
N.
Peled,
M.
Kris,
J.
Mazières,
J.
Gainor,
O.
Gautschi
(2018)
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers
Journal of Thoracic Oncology, 13
-
C.
Belli,
F.
Penault-Llorca,
M.
Ladanyi,
N.
Normanno,
J.
Scoazec,
L.
Lacroix,
J.
Reis-Filho,
V.
Subbiah,
J.
Gainor,
V.
Endris,
M.
Repetto,
A.
Drilon,
A.
Scarpa,
F.
André,
J.
Douillard,
G.
Curigliano
(2021)
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
Annals of oncology : official journal of the European Society for Medical Oncology
-
(
El OstaB
RamalingamS
. RET fusion: joining the ranks of targetable molecular drivers in NSCLC. JTO Clin Res Reports
2020; 1: 1–11.)
El OstaB
RamalingamS
. RET fusion: joining the ranks of targetable molecular drivers in NSCLC. JTO Clin Res Reports
2020; 1: 1–11.
El OstaB
RamalingamS
. RET fusion: joining the ranks of targetable molecular drivers in NSCLC. JTO Clin Res Reports
2020; 1: 1–11.,
El OstaB
RamalingamS
. RET fusion: joining the ranks of targetable molecular drivers in NSCLC. JTO Clin Res Reports
2020; 1: 1–11.
-
(2014)
RETrearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
-
(2020)
Molecular characterization and clinical outcomes in RETrearranged NSCLC
-
(
KatoS
SubbiahV
MarchlikE
, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res
2017; 23: 1988–1997.27683183)
KatoS
SubbiahV
MarchlikE
, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res
2017; 23: 1988–1997.27683183
KatoS
SubbiahV
MarchlikE
, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res
2017; 23: 1988–1997.27683183,
KatoS
SubbiahV
MarchlikE
, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res
2017; 23: 1988–1997.27683183
-
S.
Kato,
V.
Subbiah,
E.
Marchlik,
Sheryl
Elkin,
J.
Carter,
R.
Kurzrock
(2016)
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Clinical Cancer Research, 23
-
(
CaiW
SuC
LiX
, et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer
2013; 119: 1486–1494.23378251)
CaiW
SuC
LiX
, et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer
2013; 119: 1486–1494.23378251
CaiW
SuC
LiX
, et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer
2013; 119: 1486–1494.23378251,
CaiW
SuC
LiX
, et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer
2013; 119: 1486–1494.23378251
-
(
MazieresJ
DrilonA
LusqueA
, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol
2019; 30: 1321–1328.31125062)
MazieresJ
DrilonA
LusqueA
, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol
2019; 30: 1321–1328.31125062
MazieresJ
DrilonA
LusqueA
, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol
2019; 30: 1321–1328.31125062,
MazieresJ
DrilonA
LusqueA
, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol
2019; 30: 1321–1328.31125062
-
Huijuan
Wang,
Ziqi
Wang,
Guowei
Zhang,
Mina
Zhang,
Xiaojuan
Zhang,
Haixia
Li,
Xuanxuan
Zheng,
Zhiyong
Ma
(2019)
Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
Cancer Medicine, 9
-
(2020)
Realworld evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan
-
(
TanAC
SeetAOL
LaiGGY
, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol
2020; 15: 1928–1934.32866654)
TanAC
SeetAOL
LaiGGY
, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol
2020; 15: 1928–1934.32866654
TanAC
SeetAOL
LaiGGY
, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol
2020; 15: 1928–1934.32866654,
TanAC
SeetAOL
LaiGGY
, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol
2020; 15: 1928–1934.32866654